Serum inhibin B level in adolescent female IDDM

Patient with insulin dependant diabetes mellitus [IDDM] are liable to changes in the control of release of prolactin, lutenizing hormone [LH], and follicle stimulating hormone [FSH]. These changes may be due to altered hypothalamus-pituitary regulating mechanism. Inhibin is a peptide member of transforming growth factor family [TGF beta]. It is secreted by granulose and theca cells of the ovary. Its secretion from granulose cells is stimulated by FSH. The aim of the present work is to spotlight the exocrine and endocrine function in female adolescent with IDDM.20 adolescent female patients with IDDM [their ages ranging from I Ito 16 years] were subjected to history taking, clinical evaluation, serum estradio and FSH, LH and inhibin B level. Our patients showed no significant difference as regards serum estradiol, FSH, LH and serum inhibin B level when compared with the control group. Whereas serum level of some hormones [FSH, LH and inhibin B] were significantly increase in 10DM patients with regular menstrual cycles when compared with the 10DM patients with irregular menstrual cycles. No significant difference between the control group and IDDM patient with good, moderate or poor metabolic control were found as regards serum estradiol level, FSH, LH and serum inhibin B level. We conclude that our young diabetic females after mean disease duration of 9 years and various metabolic control, had serum inhibin B and gonadotropins comparable to those of normal subjects. Therefore they seem to have a regular ovarian function and in particular granulosa and theca cells despite of sustained hyperglycemia

Pulmonary function changes in patient beta thalassaemia major

Thalassaemia major is the most common cause of chronic hemolytic anemia in Mediterranean population Aggressive blood transfusion therapy for thalassaemia permit better growth and preventing progressive marrow expansion and cosmetic problems. Iron overload from blood transfusion is the main cause of organ dysfunction. Lung function abnormalities in thalassaemia major are various and complex. The aim of the present work is to assess pulmonary function changes in beta thalassaemia major patients. Twenty-four children [14 males and 10 females with their ages ranging from 5 to 15 years] with beta thalassaemia major treated with desferoxamine injection were subjected to history taking, clinical evaluation, Echocardiography and pulmonary function tests [FVC and FEV1/FVC]. Patients with beta thalassaemia major showed significant decrease in FVC [83.37% +/- 6.79%of the predicted] when compared with the control group [92% +/- 1.76%of the predicted] [P=0.001]. This decreased FVC is positively correlated with hemoglobin concentration [P=0.001] and pulmonary acceleration time [P=0001] and negatively with left ventricular end diastolic diameter [P=0.001] and left ventricular end systolic diameter [P=0.001]. There was no significant difference between control group and patients with beta thalassaemia major as regards FEV1/FVC. This decrease in FVC was observed in all groups of the study with either regular or irregular intake of iron chelating agent when compared with control group. This restrictive impaired lung function can be explained by pulmonary hemosiderosis due to repeated blood transfusion and increased gastrointestinal iron absorption and also maybe related to cardiac changes that occurred in these patients